These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 29938855)

  • 1. Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas.
    Jain D; Sukumar S; Mohan A; Iyer VK
    Cytopathology; 2018 Dec; 29(6):550-557. PubMed ID: 29938855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
    Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
    Chauhan A; Siegel L; Freese R; Racila E; Stewart J; Amin K
    Diagn Cytopathol; 2021 Mar; 49(3):355-362. PubMed ID: 33142053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
    Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
    Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.
    Zou Y; Xu L; Tang Q; You Q; Wang X; Ding W; Zhao J; Ren G
    BMC Cancer; 2020 Apr; 20(1):344. PubMed ID: 32321471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
    Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer.
    Capizzi E; Ricci C; Giunchi F; Zagnoni S; Ceccarelli C; Gómez BUÁ; Casolari L; Gelsomino F; Trisolini R; Fiorentino M; Ardizzoni A
    Lung Cancer; 2018 Dec; 126():9-14. PubMed ID: 30527198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay.
    Munari E; Zamboni G; Sighele G; Marconi M; Sommaggio M; Lunardi G; Rossi G; Cavazza A; Moretta F; Gilioli E; Caliò A; Netto GJ; Hoque MO; Martignoni G; Brunelli M; Vacca P; Moretta L; Bogina G
    Cancer Cytopathol; 2019 Feb; 127(1):52-61. PubMed ID: 30500997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing PD-L1 evaluation on cytological samples from advanced non-small-cell lung cancer.
    Bozzetti C; Squadrilli A; Nizzoli R; Lagrasta C; Gasparro D; Majori M; Filippo M; Becchi G; Azzoni C; Campanini N; Pedrazzi G; Zavani A; Silini EM; Tiseo M; Gnetti L
    Immunotherapy; 2020 Feb; 12(3):183-193. PubMed ID: 32066299
    [No Abstract]   [Full Text] [Related]  

  • 11. The detection of PD-L1 expression on liquid-based cytology in pleural effusion of lung adenocarcinoma and its prognostic evaluation: Between paired liquid-based cytology and cell block samples.
    Ma H; Jia J; Sun Z; Xiao X; Liang S; Zhao L; Zhang Z
    Diagn Cytopathol; 2024 May; 52(5):235-242. PubMed ID: 38263766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.
    Parra ER; Villalobos P; Mino B; Rodriguez-Canales J
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):83-93. PubMed ID: 28719380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-blocks are suitable material for programmed cell death ligand-1 immunohistochemistry: Comparison of cell-blocks and matched surgical resection specimens in lung cancer.
    Pak MG; Roh MS
    Cytopathology; 2019 Nov; 30(6):578-585. PubMed ID: 31209979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens.
    Bubendorf L; Conde E; Cappuzzo F; Langfort R; Schildhaus HU; Votruba J; Concha-López Á; Esteban-Rodriguez I; Feng J; Devenport J; Boyiddle C; Morris S; Trunzer K; Kerr KM
    Cancer Cytopathol; 2020 Dec; 128(12):928-938. PubMed ID: 32721105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.
    Koomen BM; van der Starre-Gaal J; Vonk JM; von der Thüsen JH; van der Meij JJC; Monkhorst K; Willems SM; Timens W; 't Hart NA
    Cancer Cytopathol; 2021 Apr; 129(4):304-317. PubMed ID: 33108706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Programmed Death-Ligand 1 (PD-L1) Immunohistochemical Expression on Cytology Specimens in Non-Small Cell Lung Carcinoma.
    Hernandez A; Brandler TC; Zhou F; Moreira AL; Schatz-Siemers N; Simsir A
    Am J Clin Pathol; 2019 Mar; 151(4):403-415. PubMed ID: 30534975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of programmed death ligand 1 expression in paired cytologic and histologic specimens of non-small cell lung cancer.
    Daverio M; Patrucco F; Gavelli F; Airoldi C; Sciortino G; Chiaramonte C; Rena O; Balbo PE; Boldorini RL
    Cancer Cytopathol; 2020 Aug; 128(8):580-588. PubMed ID: 32463583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
    Jug R; Giovacchini CX; Liu B; Green CL; Clarke JM; Mahmood K; Pavlisko EN
    J Am Soc Cytopathol; 2020; 9(6):485-493. PubMed ID: 32336671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.
    Russell-Goldman E; Kravets S; Dahlberg SE; Sholl LM; Vivero M
    Cancer Cytopathol; 2018 Apr; 126(4):253-263. PubMed ID: 29405663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.